- Home
- MCRB vs BFIN Comparison
MCRB vs BFIN Comparison
Compare MCRB & BFIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MCRB
- BFIN
- Stock Information
- Founded
- MCRB 2010
- BFIN 1924
- Country
- MCRB United States
- BFIN United States
- Employees
- MCRB N/A
- BFIN N/A
- Industry
- MCRB Biotechnology: Pharmaceutical Preparations
- BFIN Savings Institutions
- Sector
- MCRB Health Care
- BFIN Finance
- Exchange
- MCRB Nasdaq
- BFIN Nasdaq
- Market Cap
- MCRB 141.9M
- BFIN 146.7M
- IPO Year
- MCRB 2015
- BFIN N/A
- Fundamental
- Price
- MCRB $10.08
- BFIN $12.24
- Analyst Decision
- MCRB Hold
- BFIN
- Analyst Count
- MCRB 5
- BFIN 0
- Target Price
- MCRB $80.00
- BFIN N/A
- AVG Volume (30 Days)
- MCRB 128.1K
- BFIN 21.0K
- Earning Date
- MCRB 05-07-2025
- BFIN 04-25-2025
- Dividend Yield
- MCRB N/A
- BFIN 3.28%
- EPS Growth
- MCRB N/A
- BFIN N/A
- EPS
- MCRB 0.02
- BFIN 0.36
- Revenue
- MCRB N/A
- BFIN $48,547,000.00
- Revenue This Year
- MCRB N/A
- BFIN $2.37
- Revenue Next Year
- MCRB N/A
- BFIN $8.53
- P/E Ratio
- MCRB $575.90
- BFIN $34.21
- Revenue Growth
- MCRB N/A
- BFIN N/A
- 52 Week Low
- MCRB $7.18
- BFIN $9.60
- 52 Week High
- MCRB $30.60
- BFIN $13.97
- Technical
- Relative Strength Index (RSI)
- MCRB 44.43
- BFIN 49.59
- Support Level
- MCRB $7.18
- BFIN $11.58
- Resistance Level
- MCRB $10.55
- BFIN $12.41
- Average True Range (ATR)
- MCRB 1.72
- BFIN 0.48
- MACD
- MCRB -0.03
- BFIN 0.06
- Stochastic Oscillator
- MCRB 46.63
- BFIN 83.06
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.
About BFIN BankFinancial Corporation
BankFinancial Corp is a full-service, national bank providing banking, financial planning and fiduciary services to individuals, families and businesses in the Chicago metropolitan area and on a regional or national basis for commercial finance, healthcare finance, equipment finance, commercial real estate finance and treasury management business customers. The Bank offers its customers a broad range of loan, deposit, trust and other financial products and services through approximately 18 full-service banking offices located in Cook, DuPage, Lake and Will Counties, Illinois and through its Internet Branch.